We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Albemarle (ALB - Free Report) ended the recent trading session at $86.88, demonstrating a -1.38% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.26%. At the same time, the Dow added 0.15%, and the tech-heavy Nasdaq gained 0.48%.
The specialty chemicals company's stock has climbed by 3.74% in the past month, falling short of the Basic Materials sector's gain of 4.08% and outpacing the S&P 500's gain of 2.87%.
Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to go public on November 5, 2025. The company is forecasted to report an EPS of -$0.97, showcasing a 37.42% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $1.27 billion, indicating a 5.92% downward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$1.85 per share and a revenue of $4.98 billion, signifying shifts of +20.94% and -7.48%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Albemarle. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.47% higher. Right now, Albemarle possesses a Zacks Rank of #3 (Hold).
The Chemical - Diversified industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 228, which puts it in the bottom 8% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Albemarle (ALB) Stock Drops Despite Market Gains: Important Facts to Note
Albemarle (ALB - Free Report) ended the recent trading session at $86.88, demonstrating a -1.38% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.26%. At the same time, the Dow added 0.15%, and the tech-heavy Nasdaq gained 0.48%.
The specialty chemicals company's stock has climbed by 3.74% in the past month, falling short of the Basic Materials sector's gain of 4.08% and outpacing the S&P 500's gain of 2.87%.
Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to go public on November 5, 2025. The company is forecasted to report an EPS of -$0.97, showcasing a 37.42% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $1.27 billion, indicating a 5.92% downward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$1.85 per share and a revenue of $4.98 billion, signifying shifts of +20.94% and -7.48%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Albemarle. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.47% higher. Right now, Albemarle possesses a Zacks Rank of #3 (Hold).
The Chemical - Diversified industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 228, which puts it in the bottom 8% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.